Recently, Fosun Pharma (stock codes: 600196.SH / 2196.HK) has seen its share prices rise simultaneously on both the Shanghai and Hong Kong stock exchanges, drawing significant investor attention. This upward movement is driven by multiple positive factors. Firstly, the company’s Q1 2024 financial report showed solid growth in both revenue and net profit, with its core pharmaceutical business performing strongly. Secondly, Fosun Pharma has made notable progress in innovative drug development, with several candidates advancing into late-stage clinical trials, bolstering market confidence in its long-term growth potential. Additionally, ongoing improvements in China’s healthcare policies and rising global demand for high-quality domestically produced medicines have created new opportunities for Fosun Pharma, a leading integrated pharmaceutical company in China. Notably, enhanced cross-border investment mechanisms between the mainland and Hong Kong have also increased foreign investors’ interest in A+H dual-listed stocks, further supporting the synchronized rally. Analysts believe that, backed by strong fundamentals and improving market sentiment, Fosun Pharma is well-positioned for continued stable performance.
近日，复星医药（股票代码：600196.SH / 2196.HK）在A股和港股市场同步上涨，引发投资者广泛关注。此次股价上扬主要受多重利好因素推动。首先，公司近期公布的2024年第一季度财报显示，营收与净利润均实现稳健增长，核心制药业务表现强劲。其次，复星医药在创新药研发方面取得重要进展，多个候选药物进入临床后期阶段，增强了市场对其长期增长潜力的信心。此外，随着中国医疗健康政策持续优化，以及全球对高质量国产药品需求上升，复星医药作为国内领先的综合性医药企业，正迎来新的发展机遇。值得注意的是，陆港两地资金流动机制的完善也提升了外资对A+H股配置的积极性，进一步助推了复星医药在两地市场的同步走强。分析人士认为，在基本面支撑与市场情绪回暖的双重驱动下，复星医药有望维持稳健表现。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/1244.html